subscribeSubscribe
Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide

Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide
GLOBENEWSWIRE
05 Jan 2023
Share Share
Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma

Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma
Amber Tong ENDPTS
25 Sep 2019
Share Share
Regeneron preps for 2020 filing for new cholesterol drug after trial success

Regeneron preps for 2020 filing for new cholesterol drug after trial success
PHARMAPHORUM
18 Aug 2019
Share Share
Armed stellar if niche PhIII, Regeneron steers `breakthrough` cholesterol drug

Armed stellar if niche PhIII, Regeneron steers `breakthrough` cholesterol drug
Amber Tong ENDPTS
14 Aug 2019
Share Share
Amryt to expand rare disease portfolio with $311m Aegerion merger

Amryt to expand rare disease portfolio with $311m Aegerion merger
Richard Staines PHARMAPHORUM
23 May 2019
Share Share
NHS England okays funding for cholesterol-lowering drug

NHS England okays funding for cholesterol-lowering drug
Richard Staines PHARMAPHORUM
09 Jul 2018
Share Share
Sticker Shock: The Real Cost Of America`s 10 Most Expensive Drugs

Sticker Shock: The Real Cost Of America`s 10 Most Expensive Drugs
Nicole Fisher FORBES
26 Jun 2018
Share Share
U.S. judge sentences Novelion`s Aegerion in drug marketing case

U.S. judge sentences Novelion`s Aegerion in drug marketing case
Nate Raymond REUTERS
01 Feb 2018
Share Share
Aegerion pleads guilty to US marketing violations

Aegerion pleads guilty to US marketing violations
G. Underwood PHARMA TIMES
26 Sep 2017
Share Share
Aegerion introduces Juxtapid in Japan for familial hypercholesterolemia

Aegerion introduces Juxtapid in Japan for familial hypercholesterolemia
PHARMABIZ
20 Dec 2016
Share Share